So, I have not seen this good of a squeeze setup in a long time. Let's take a look at the goodies.
Data from Ortex.com
Average cost to borrow currently 255%
Estimated percent of free float on loan 89.93%
Shares on loan has risen 190% in the last 7 days
Utilization is at 98.79%
I think $LGVN could be the best short squeeze setup I've seen in a long time...
The Longeveron Inc. (NASDAQ: LGVN) Lead MSC Product Lomecel-B is Being Clinically Studied for Five Different Indications
You may follow the biopharma sector, or at least have an interest in it. Longeveron Inc. (NASDAQ: LGVN), is a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions and they have an interesting lead product with good potential.
That flagship product, Lomecel-B, is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. MSCs are used by several pharma developers right now because a single donated cell from bone marrow in this case, or donated umbilical cords in others, can be expanded into millions of MSCs.
Medicinal Signaling Cells are also known as Mesenchymal Stem Cells, the pharma sector is in the process of renaming them. They have been studied for thirty years to evaluate their potential for human tissue repair.
The company is currently studying Lomecel-B for five different indications; Aging Frailty (why do some of us age better than others), Alzheimer’s, Metabolic Syndrome (combination of diabetes, high blood pressure, high cholesterol, heart disease, etc.), acute respiratory distress syndrome (often associated with covid), and Hypoplastic Left Heart Syndrome (see below). The studies for these indications range from pre-clinical to a Phase 2B clinical trial and the exact status of each is detailed on the company website.
I can’t think pf any other small-cap pharma companies that have one product being tested and studied for five different indications. If LGVN has success in one of the bigger markets they are testing for, the implications could be huge. MSCs offer a lot of potential in future medicine.
On November 18th, the company said its Lomecel-B for the treatment of a congenital heart defect in infants (Hypoplastic Left Heart Syndrome or HLHS) affecting about 1,000 babies a year was granted rare pediatric disease (RPD) designation by the FDA. HLHS is a severe congenital birth defect in which the left ventricle of the heart is either severely underdeveloped or missing. LGVN is testing Lomecel-B as a potential combinatorial therapy candidate to surgical intervention for improving long-term cardiac function in HLHS patients.
While the market for Lomecel-B to treat HLHS may be small, the other indications it’s being studied for are huge. LGVN has four different trials running concurrently for aging frailty, two in the U.S., one in Japan and one in the Bahamas. Signs and symptoms of aging frailty include reduced activity, slowness, involuntary weight loss, weakness, and fatigue. Over eight million seniors suffer from aging frailty in the U.S. alone, and geriatricians believe it’s a treatable condition.
I want to talk about the market potential for the indications LGVN is involved with. I'll have that put together and posted soon.
Privacy policy and disclosure https://us3.campaign-archive.com/?e=[UNIQID]&u=3a207043349295e229010b31c&id=9fad3c5b2e
Data from Ortex.com
Average cost to borrow currently 255%
Estimated percent of free float on loan 89.93%
Shares on loan has risen 190% in the last 7 days
Utilization is at 98.79%
I think $LGVN could be the best short squeeze setup I've seen in a long time...
The Longeveron Inc. (NASDAQ: LGVN) Lead MSC Product Lomecel-B is Being Clinically Studied for Five Different Indications
You may follow the biopharma sector, or at least have an interest in it. Longeveron Inc. (NASDAQ: LGVN), is a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions and they have an interesting lead product with good potential.
That flagship product, Lomecel-B, is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. MSCs are used by several pharma developers right now because a single donated cell from bone marrow in this case, or donated umbilical cords in others, can be expanded into millions of MSCs.
Medicinal Signaling Cells are also known as Mesenchymal Stem Cells, the pharma sector is in the process of renaming them. They have been studied for thirty years to evaluate their potential for human tissue repair.
The company is currently studying Lomecel-B for five different indications; Aging Frailty (why do some of us age better than others), Alzheimer’s, Metabolic Syndrome (combination of diabetes, high blood pressure, high cholesterol, heart disease, etc.), acute respiratory distress syndrome (often associated with covid), and Hypoplastic Left Heart Syndrome (see below). The studies for these indications range from pre-clinical to a Phase 2B clinical trial and the exact status of each is detailed on the company website.
I can’t think pf any other small-cap pharma companies that have one product being tested and studied for five different indications. If LGVN has success in one of the bigger markets they are testing for, the implications could be huge. MSCs offer a lot of potential in future medicine.
On November 18th, the company said its Lomecel-B for the treatment of a congenital heart defect in infants (Hypoplastic Left Heart Syndrome or HLHS) affecting about 1,000 babies a year was granted rare pediatric disease (RPD) designation by the FDA. HLHS is a severe congenital birth defect in which the left ventricle of the heart is either severely underdeveloped or missing. LGVN is testing Lomecel-B as a potential combinatorial therapy candidate to surgical intervention for improving long-term cardiac function in HLHS patients.
While the market for Lomecel-B to treat HLHS may be small, the other indications it’s being studied for are huge. LGVN has four different trials running concurrently for aging frailty, two in the U.S., one in Japan and one in the Bahamas. Signs and symptoms of aging frailty include reduced activity, slowness, involuntary weight loss, weakness, and fatigue. Over eight million seniors suffer from aging frailty in the U.S. alone, and geriatricians believe it’s a treatable condition.
I want to talk about the market potential for the indications LGVN is involved with. I'll have that put together and posted soon.
Privacy policy and disclosure https://us3.campaign-archive.com/?e=[UNIQID]&u=3a207043349295e229010b31c&id=9fad3c5b2e
